CA2849055C - N-substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders - Google Patents
N-substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders Download PDFInfo
- Publication number
- CA2849055C CA2849055C CA2849055A CA2849055A CA2849055C CA 2849055 C CA2849055 C CA 2849055C CA 2849055 A CA2849055 A CA 2849055A CA 2849055 A CA2849055 A CA 2849055A CA 2849055 C CA2849055 C CA 2849055C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- compounds
- pharmaceutical composition
- img
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1116335.9 | 2011-09-21 | ||
| GBGB1116335.9A GB201116335D0 (en) | 2011-09-21 | 2011-09-21 | A method of treating or preventing affective disorders |
| PCT/IB2012/054700 WO2013042005A1 (en) | 2011-09-21 | 2012-09-10 | N- substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2849055A1 CA2849055A1 (en) | 2013-03-28 |
| CA2849055C true CA2849055C (en) | 2019-11-26 |
Family
ID=44937647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2849055A Expired - Fee Related CA2849055C (en) | 2011-09-21 | 2012-09-10 | N-substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9133103B2 (enExample) |
| EP (1) | EP2758046B1 (enExample) |
| JP (1) | JP6067022B2 (enExample) |
| CN (1) | CN103826622B (enExample) |
| AU (1) | AU2012311183B2 (enExample) |
| CA (1) | CA2849055C (enExample) |
| DK (1) | DK2758046T3 (enExample) |
| ES (1) | ES2559294T3 (enExample) |
| GB (1) | GB201116335D0 (enExample) |
| IL (1) | IL231609A (enExample) |
| WO (1) | WO2013042005A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015173813A1 (en) * | 2014-05-14 | 2015-11-19 | Novaremed Ltd. | Pharmaceutical composition comprising stereoisomers of n-(1-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide for the prevention and treatment of type ii diabetes |
| CN107011313B (zh) | 2016-01-27 | 2021-11-30 | 天士力医药集团股份有限公司 | 取代桂皮酰胺衍生物在制备抗焦虑药物中的应用 |
| EP3939578A1 (en) * | 2020-07-13 | 2022-01-19 | Novaremed Ltd. | Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2535975T3 (es) * | 2002-10-03 | 2015-05-19 | Novaremed Ltd. | Compuestos para su uso en el tratamiento de enfermedades autoinmunitarias, enfermedades inmunoalérgicas y rechazo de trasplantes de órganos o tejidos |
| US7674829B2 (en) * | 2004-03-26 | 2010-03-09 | Novaremed Limited | Compounds for the treatment of AIDS and other viral diseases |
| MXPA06013162A (es) * | 2004-05-12 | 2007-02-13 | Pfizer Prod Inc | Derivados de piperidina como antagonistas de neurocinina 1 y neurocinina 3. |
| RU2309144C2 (ru) * | 2005-03-25 | 2007-10-27 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фенилсодержащие n-ацильные производные аминов, способ их получения, фармацевтическая композиция и их применение в качестве противовоспалительных и анальгетических средств |
| GB0804213D0 (en) | 2008-03-06 | 2008-04-16 | New Era Biotech Ltd | A method of printing or preventing pain |
| PL2475361T3 (pl) * | 2009-09-09 | 2020-07-13 | Novaremed Ltd. | N-podstawione benzenopropanoamidy do stosowania w leczeniu bólu i stanu zapalnego |
-
2011
- 2011-09-21 GB GBGB1116335.9A patent/GB201116335D0/en not_active Ceased
-
2012
- 2012-09-10 DK DK12780536.4T patent/DK2758046T3/da active
- 2012-09-10 JP JP2014531340A patent/JP6067022B2/ja not_active Expired - Fee Related
- 2012-09-10 US US14/346,419 patent/US9133103B2/en not_active Expired - Fee Related
- 2012-09-10 ES ES12780536.4T patent/ES2559294T3/es active Active
- 2012-09-10 EP EP12780536.4A patent/EP2758046B1/en not_active Not-in-force
- 2012-09-10 CN CN201280045760.3A patent/CN103826622B/zh not_active Expired - Fee Related
- 2012-09-10 AU AU2012311183A patent/AU2012311183B2/en not_active Ceased
- 2012-09-10 CA CA2849055A patent/CA2849055C/en not_active Expired - Fee Related
- 2012-09-10 WO PCT/IB2012/054700 patent/WO2013042005A1/en not_active Ceased
-
2014
- 2014-03-19 IL IL231609A patent/IL231609A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| HK1200353A1 (zh) | 2015-08-07 |
| CN103826622A (zh) | 2014-05-28 |
| JP2014530200A (ja) | 2014-11-17 |
| ES2559294T3 (es) | 2016-02-11 |
| CA2849055A1 (en) | 2013-03-28 |
| US9133103B2 (en) | 2015-09-15 |
| JP6067022B2 (ja) | 2017-01-25 |
| EP2758046B1 (en) | 2015-10-21 |
| EP2758046A1 (en) | 2014-07-30 |
| AU2012311183B2 (en) | 2016-09-22 |
| WO2013042005A1 (en) | 2013-03-28 |
| IL231609A0 (en) | 2014-05-28 |
| CN103826622B (zh) | 2016-06-08 |
| DK2758046T3 (da) | 2016-02-01 |
| GB201116335D0 (en) | 2011-11-02 |
| US20140275273A1 (en) | 2014-09-18 |
| AU2012311183A1 (en) | 2014-04-03 |
| IL231609A (en) | 2016-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2226435T3 (es) | Metodos de uso y composiciones que comprenden inhibidores de la recaptacion de dopamina. | |
| AU2014248849B2 (en) | Treatment of cataplexy | |
| CN103025326B (zh) | 治疗不安腿综合征的方法 | |
| CN102781436B (zh) | 纤维肌痛综合征的治疗方法 | |
| RU2760558C2 (ru) | Целевой лекарственный препарат и новые композиции, комбинации на его основе и способы их применения | |
| KR20130112706A (ko) | 양극성 장애의 치료방법 | |
| ES2260195T3 (es) | Metodos de producir (r)-y (s)-didesmetil-sibutramina opticamente pura. | |
| US20160317479A1 (en) | Method of treating or preventing pain | |
| CA2849055C (en) | N-substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders | |
| JP6016179B2 (ja) | 疼痛の治療又は予防用医薬組成物 | |
| EA015483B1 (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ | |
| JPWO2005079845A1 (ja) | 片頭痛予防薬 | |
| HK1200353B (en) | N-substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders | |
| US20090012178A1 (en) | Benzoxazocines and Their Therapeutic Use | |
| JP2011506352A (ja) | 4−[2,3−ジフルオロ−6−(2−フルオロ−4−メチル−フェニルスルファニル)−フェニル]−ピペリジン | |
| WO2005118522A1 (en) | Monomethylphytosphingosine- polyethylenegly col and the composition for anti-cancer containing the same | |
| HK1178796B (en) | Methods of treating restless legs syndrome | |
| HK1179523B (en) | N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170908 |
|
| MKLA | Lapsed |
Effective date: 20210910 |